Skip to main content
Top
Published in: Familial Cancer 1/2018

01-01-2018 | Original Article

Somatic mutations of the coding microsatellites within the beta-2-microglobulin gene in mismatch repair-deficient colorectal cancers and adenomas

Authors: Mark Clendenning, Alvin Huang, Harindra Jayasekara, Marie Lorans, Susan Preston, Neil O’Callaghan, Bernard J. Pope, Finlay A. Macrae, Ingrid M. Winship, Roger L. Milne, Graham G. Giles, Dallas R. English, John L. Hopper, Aung K. Win, Mark A. Jenkins, Melissa C. Southey, Christophe Rosty, Daniel D. Buchanan, On behalf of investigators from the Melbourne Collaborative Cohort Study and the Australasian Colorectal Cancer Family Registry Cohort

Published in: Familial Cancer | Issue 1/2018

Login to get access

Abstract

In colorectal cancers (CRCs) with tumour mismatch repair (MMR) deficiency, genes involved in the host immune response that contain microsatellites in their coding regions, including beta-2-microglobulin (B2M), can acquire mutations that may alter the immune response, tumour progression and prognosis. We screened the coding microsatellites within B2M for somatic mutations in MMR-deficient CRCs and adenomas to determine associations with tumour subtypes, clinicopathological features and survival. Incident MMR-deficient CRCs from Australasian Colorectal Cancer Family Registry (ACCFR) and the Melbourne Collaborative Cohort Study participants (n = 144) and 63 adenomas from 41 MMR gene mutation carriers from the ACCFR were screened for somatic mutations within five coding microsatellites of B2M. Hazard ratios (HR) and 95% confidence intervals (CI) for overall survival by B2M mutation status were estimated using Cox regression, adjusting for age at CRC diagnosis, sex, AJCC stage and grade. B2M mutations occurred in 30 (20.8%) of the 144 MMR-deficient CRCs (29% of the MLH1-methylated, 17% of the Lynch syndrome and 9% of the suspected Lynch CRCs). No B2M mutations were identified in the 63 adenomas tested. B2M mutations differed by site, stage, grade and lymphocytic infiltration although none reached statistical significance (p > 0.05). The HR for overall survival for B2M mutated CRC was 0.65 (95% CI 0.29–1.48) compared with B2M wild-type. We observed differences in B2M mutation status in MMR-deficient CRC by tumour subtypes, site, stage, grade, immune infiltrate and for overall survival that warrant further investigation in larger studies before B2M mutation status can be considered to have clinical utility.
Appendix
Available only for authorised users
Literature
2.
3.
go back to reference Thibodeau SN, Bren G, Schaid D (1993) Microsatellite instability in cancer of the proximal colon. Science 260(5109):816–819CrossRefPubMed Thibodeau SN, Bren G, Schaid D (1993) Microsatellite instability in cancer of the proximal colon. Science 260(5109):816–819CrossRefPubMed
4.
5.
go back to reference Ligtenberg MJ, Kuiper RP, Chan TL et al (2009) Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat Genet 41(1):112–117. doi:10.1038/ng.283 CrossRefPubMed Ligtenberg MJ, Kuiper RP, Chan TL et al (2009) Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat Genet 41(1):112–117. doi:10.​1038/​ng.​283 CrossRefPubMed
6.
go back to reference Herman JG, Umar A, Polyak K et al (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 95(12):6870–6875CrossRefPubMedPubMedCentral Herman JG, Umar A, Polyak K et al (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 95(12):6870–6875CrossRefPubMedPubMedCentral
8.
10.
go back to reference Buchanan DD, Rosty C, Clendenning M, Spurdle AB, Win AK (2014) Clinical problems of colorectal cancer and endometrial cancer cases with unknown cause of tumor mismatch repair deficiency (suspected Lynch syndrome). Appl Clin Genet 7:183–193. doi:10.2147/TACG.S48625 PubMedPubMedCentral Buchanan DD, Rosty C, Clendenning M, Spurdle AB, Win AK (2014) Clinical problems of colorectal cancer and endometrial cancer cases with unknown cause of tumor mismatch repair deficiency (suspected Lynch syndrome). Appl Clin Genet 7:183–193. doi:10.​2147/​TACG.​S48625 PubMedPubMedCentral
13.
15.
go back to reference Yamamoto H, Yamashita K, Perucho M (2001) Somatic mutation of the beta2-microglobulin gene associates with unfavorable prognosis in gastrointestinal cancer of the microsatellite mutator phenotype. Gastroenterology 120(6):1565–1567CrossRefPubMed Yamamoto H, Yamashita K, Perucho M (2001) Somatic mutation of the beta2-microglobulin gene associates with unfavorable prognosis in gastrointestinal cancer of the microsatellite mutator phenotype. Gastroenterology 120(6):1565–1567CrossRefPubMed
18.
go back to reference Bicknell DC, Kaklamanis L, Hampson R, Bodmer WF, Karran P (1996) Selection for beta 2-microglobulin mutation in mismatch repair-defective colorectal carcinomas. Curr Biol 6(12):1695–1697CrossRefPubMed Bicknell DC, Kaklamanis L, Hampson R, Bodmer WF, Karran P (1996) Selection for beta 2-microglobulin mutation in mismatch repair-defective colorectal carcinomas. Curr Biol 6(12):1695–1697CrossRefPubMed
20.
go back to reference Giles GG, English DR (2002) The Melbourne collaborative cohort study. IARC Sci Publ 156:69–70PubMed Giles GG, English DR (2002) The Melbourne collaborative cohort study. IARC Sci Publ 156:69–70PubMed
21.
go back to reference Newcomb PA, Baron J, Cotterchio M et al (2007) Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomark Prev 16(11):2331–2343CrossRef Newcomb PA, Baron J, Cotterchio M et al (2007) Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomark Prev 16(11):2331–2343CrossRef
23.
go back to reference Walsh MD, Buchanan DD, Pearson SA et al (2012) Immunohistochemical testing of conventional adenomas for loss of expression of mismatch repair proteins in Lynch syndrome mutation carriers: a case series from the Australasian site of the colon cancer family registry. Mod Pathol 25(5):722–730. doi:10.1038/modpathol.2011.209 CrossRefPubMedPubMedCentral Walsh MD, Buchanan DD, Pearson SA et al (2012) Immunohistochemical testing of conventional adenomas for loss of expression of mismatch repair proteins in Lynch syndrome mutation carriers: a case series from the Australasian site of the colon cancer family registry. Mod Pathol 25(5):722–730. doi:10.​1038/​modpathol.​2011.​209 CrossRefPubMedPubMedCentral
25.
go back to reference Korn EL, Graubard BI, Midthune D (1997) Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol 145(1):72–80CrossRefPubMed Korn EL, Graubard BI, Midthune D (1997) Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol 145(1):72–80CrossRefPubMed
27.
go back to reference Linnebacher M, Gebert J, Rudy W et al (2001) Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. Int J Cancer 93(1):6–11CrossRefPubMed Linnebacher M, Gebert J, Rudy W et al (2001) Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. Int J Cancer 93(1):6–11CrossRefPubMed
29.
go back to reference Ripberger E, Linnebacher M, Schwitalle Y, Gebert J, von Knebel Doeberitz M (2003) Identification of an HLA-A0201-restricted CTL epitope generated by a tumor-specific frameshift mutation in a coding microsatellite of the OGT gene. J Clin Immunol 23(5):415–423CrossRefPubMed Ripberger E, Linnebacher M, Schwitalle Y, Gebert J, von Knebel Doeberitz M (2003) Identification of an HLA-A0201-restricted CTL epitope generated by a tumor-specific frameshift mutation in a coding microsatellite of the OGT gene. J Clin Immunol 23(5):415–423CrossRefPubMed
30.
go back to reference Schwitalle Y, Linnebacher M, Ripberger E, Gebert J, von Knebel Doeberitz M (2004) Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells. Cancer Immun 4:14PubMed Schwitalle Y, Linnebacher M, Ripberger E, Gebert J, von Knebel Doeberitz M (2004) Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells. Cancer Immun 4:14PubMed
39.
go back to reference Echterdiek F, Janikovits J, Staffa L et al (2016) Low density of FOXP3-positive T cells in normal colonic mucosa is related to the presence of beta2-microglobulin mutations in Lynch syndrome-associated colorectal cancer. Oncoimmunology 5(2):e1075692 doi:10.1080/2162402X.2015.1075692 CrossRefPubMed Echterdiek F, Janikovits J, Staffa L et al (2016) Low density of FOXP3-positive T cells in normal colonic mucosa is related to the presence of beta2-microglobulin mutations in Lynch syndrome-associated colorectal cancer. Oncoimmunology 5(2):e1075692 doi:10.​1080/​2162402X.​2015.​1075692 CrossRefPubMed
Metadata
Title
Somatic mutations of the coding microsatellites within the beta-2-microglobulin gene in mismatch repair-deficient colorectal cancers and adenomas
Authors
Mark Clendenning
Alvin Huang
Harindra Jayasekara
Marie Lorans
Susan Preston
Neil O’Callaghan
Bernard J. Pope
Finlay A. Macrae
Ingrid M. Winship
Roger L. Milne
Graham G. Giles
Dallas R. English
John L. Hopper
Aung K. Win
Mark A. Jenkins
Melissa C. Southey
Christophe Rosty
Daniel D. Buchanan
On behalf of investigators from the Melbourne Collaborative Cohort Study and the Australasian Colorectal Cancer Family Registry Cohort
Publication date
01-01-2018
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 1/2018
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-017-0013-y

Other articles of this Issue 1/2018

Familial Cancer 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine